Tag: Patients
Search News
Clinical study to investigate new personalised treatment for ovarian cancer
14th March 2022
Dr Michelle Lockley from Barts Cancer Institute at Queen Mary University of London has received funding from Barts Charity and the Anticancer Fund to investigate a new personalised treatment approach for ovarian cancer that has returned after previous chemotherapy.
Read more
Immunotherapy significantly reduces recurrence in aggressive breast cancer
10th February 2022
An immunotherapy drug called ‘pembrolizumab’ has been shown to significantly reduce disease recurrence in patients with the most aggressive type of breast cancer, according to results from a phase III clinical trial led by Professor Peter Schmid from Queen Mary University of London and Barts Health NHS Trust.
Read more
Blood test predicts chemotherapy resistance in prostate cancer
11th November 2021
Research conducted at Barts Cancer Institute (BCI), Queen Mary University of London, indicates that regular blood tests before and during chemotherapy for prostate cancer can detect whether or not a patient is resistant or developing resistance to treatment with a drug called docetaxel. Ms Caitlin Davies, a PhD student at BCI, presented the findings from her PhD research at the National Cancer Research Institute (NCRI) Festival, which is taking place from 8-12th November 2021.
Read more
OPTIMA: Improving treatment for cancer patients through artificial intelligence
12th October 2021
Professors Claude Chelala and Louise Jones from Barts Cancer Institute, Queen Mary University of London, are part of a €21.3 million public-private research programme that will seek to use artificial intelligence to improve care for patients with prostate, breast and lung cancer.
Read more
Combining medicine with blood cancer research
3rd September 2021
This Blood Cancer Awareness Month, we spoke with Dr John Riches, Clinical Senior Lecturer at Barts Cancer Institute (BCI), Queen Mary University of London. Dr Riches is a clinician scientist who splits his time between BCI where he leads a group researching blood cancer in our Centre for Haemato-Oncology and directs the MSc Cancer & Clinical Oncology Programme, and St Bartholemew’s Hospital where he treats blood cancer patients.
Read more
Study identifies biomarker that could help to diagnose pancreatic cancer
29th June 2021
Researchers from Barts Cancer Institute, Queen Mary University of London, have identified a protein that could be used to aid in the diagnosis of pancreatic cancer. Findings from the new study suggest that a protein called pentraxin 3 may be a specific diagnostic biomarker – or biological measure – for pancreatic cancer, with the ability to differentiate pancreatic cancer from other non-cancerous conditions of the pancreas.
Read more